Adenoviral E1A proteins exhibit a strong tumor-suppressive activity in human tumor cells. However, E1A is capable of transforming rodent and human cells in cooperation with other oncoproteins, such as activated RAS. Thus, the therapeutic use of wild-type E1A harbors the principal risk of enhancing tumor malignancy. This prompted us to construct E1A 13S cDNA-derived mutants that were unable to transform baby mouse kidney cells in cooperation with E1B and to test their tumor-suppressive activity in BLM human melanoma cells. Anchorage-independent growth in soft agar was reduced for those cell lines expressing the E1A delCR2 mutant, which lacks the entire conserved region 2 (CR2) sequences, or for cells expressing the E1A CR3Ex2 mutant, which contains CR3 plus exon 2 sequences. In contrast, cell lines expressing the entire E1A wild-type (E1A WT ) or only the exon 2 sequences (E1A Ex2 ) grew like the parental BLM cells. Moreover, inoculation of nude mice with BLM cells or cells expressing E1A Ex2 revealed large tumors after 2 weeks. In contrast, tumors derived from E1A delCR2 -or E1A CR3Ex2 -expressing cells exhibited a substantial delay in tumor growth accompanied by a loss of E1A expression in the outgrown tumors. Cell lines expressing E1A WT showed an intermediate phenotype. Thus, expression of CR3 plus exon 2 sequences is sufficient to enhance both the antioncogenic properties and the therapeutic safety of E1A in our system.
T he E1A gene of human adenoviruses (Ads) is expressed early after infection and encodes multifunctional proteins that activate and suppress the transcription of both viral and cellular genes. 1, 2 Moreover, E1A proteins transform rodent cells in cooperation with other viral or cellular oncogene products (e.g., E1B or activated cellular RAS 3 ). Recently, a strong tumor suppressor activity of E1A in several human cancer cells, including lung cancer cells, rhabdomyosarcoma cells, breast cancer cells, and RAS-transformed kidney epithelial cells, was observed. 4 -7 One mechanism of tumor suppression by E1A is the transcriptional down-regulation of the HER-2/neu promoter, which requires aminoterminal sequences as well as sequences within the conserved region1 (CR1). 8 -10 However, E1A mediates additional HER-2/neu-independent antitumorigenic mechanisms and can therefore be considered to be a broad-spectrum tumor-suppressive agent. 5 In particular, E1A seems to have an ability to convert tumor cells to normal epithelial cells. 11 These properties of the multifunctional E1A proteins led to the initiation of the first clinical trials. 12, 13 Another important feature of E1A is the suppression of metastatic potential, which has been demonstrated in a variety of cell types. 14 -16 Although the mechanisms of this suppression are not fully understood, it has been demonstrated that E1A proteins stimulate the expression of the cell adherence molecule E-cadherin, which is missing in many metastatic cells. 17 In addition, E1A suppresses the expression of matrixdegrading metalloproteases 15, 18, 19 and activates the expression of tissue inhibitors of metalloproteases 20 . Moreover, E1A proteins repress the expression of CD44 variants, which have been associated with metastatic growth, 21, 22 and seem to stimulate the NM23 metastasis suppressor gene, 23 which is associated with low metastatic potential. 24 The E1A region of Ad5 is a complex transcription unit and, due to alternative splicing, gives raise to five transcripts. Two major proteins to which most E1A functions can be ascribed are encoded by a 13S and 12S mRNA and contain 289 and 243 amino acid residues (R), respectively. They share two CRs, CR1 and CR2, which are highly homologous between different Ad serotypes. The 289R protein contains an additional CR (CR3) that harbors a strong transcriptional activation domain. 25 No specific binding of E1A proteins to DNA has been described so far; thus, transcriptional regulation by E1A appears to be indirect, by modulating the DNA interactions of several transcription factors. Among the binding partners of E1A are the tumor suppressor protein p105-RB and the related pocket proteins p107 and p130, which link E1A to core elements of the cell cycle regulatory machinery. Examples of other important E1A binding proteins are the transcriptional coactivator p300, which is involved in the regulation of many promoters, and the TATA-binding protein. 26 Functionally, the binding of these proteins plays a crucial role in many of the activities of E1A (e.g., transformation). [27] [28] [29] [30] The mechanism of tumor suppression by E1A, especially in its HER2/neu-independent fashion, is just beginning to be elucidated. 6, 7 Domains in exon 1 as well as exon 2 sequences seem to play a role in repression of transformation: 31, 32 A protein termed carboxyterminal binding protein (CtBP) was identified that binds to exon 2-encoded amino acids; E1A mutants that are defective for this binding show an enhanced metastatic potential in E1A plus RAS-transformed baby rat kidney cells. 33, 34 The gene encoding CtBP has been cloned and characterized. Its product is a 48-kDa phosphoprotein that is involved in both the lytic cycle of Ad infection and adenoviral transformation. 32 In current clinical studies genomic E1A is used, which could express up to five different proteins, with the small E1A products lacking defined functions in human cells. Moreover, the large (289R and 243R) proteins both have the full transforming potential of E1A. 12, 13 Because immortalization and transformation of human embryonic kidney cells by E1A has been successfully achieved in cooperation with E1B [35] [36] [37] and for principal considerations for using E1A as a therapeutic transgene, our aim was the construction of transformation-defective tumor-suppressing E1A derivatives originating from the defined 289R encoding cDNA as a tool for gene therapy. The 13S instead of the 12S cDNA was chosen due to its dominant transformation-suppressing effect when expressed together with the 12S mRNA species, 38 suggesting an intrinsic antitumorigenic activity within the CR3. As a tumor model, we used the BLM human melanoma cell line, which is precharacterized with respect to the down-regulation of tumor progression markers and reduction of tumorigenicity on E1A expression using the entire genomic E1 region.
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MATERIALS AND METHODS
Plasmids
The 13S cDNA of E1A was amplified by reverse transcriptase polymerase chain reaction (PCR) from 293 cells using the following primers: RT, 5Ј-ggtgttaaccacacacgcaatcacagg-3Ј; forward, 5Ј-cctccgagccgctccgacaccg-3Ј; reverse, 5Ј-tttacaccttatggcctggggc-3Ј, containing artificial HindIII/EcoRI sites, respectively. The deletion mutants were generated using the ExSite PCR-based, site-directed mutagenesis kit (Stratagene, La Jolla, Calif). All cDNA constructs were cloned into the pRc-RSV vector (Invitrogen, San Diego, Calif). The resulting constructs are E1A WT : amino acids 1-289; E1A delCR2 : deletion of amino acids 120 -138; E1A CR3Ex2 : deletion of amino acids 2-138; and E1A Ex2 : deletion of amino acids 2-186. All DNA sequencing was done in a commercial setting (Seqlab, Goettingen, Germany). For verification of constructs, double-strand sequencing was performed.
Cell lines and transfections
BLM cells 40 and the derivative cell lines were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, Md) supplemented with 10% fetal calf serum (FCS) (PAA Laboratories, Marburg, Germany). Transfections of the BLM cell line were performed by electroporation. A total of 20 g of E1A WT plasmid or the E1A deletion constructs were used. At 48 hours posttransfection, cells were selected with 800 g/mL G418 (PAA Laboratories) for 4 weeks. Resistant colonies were isolated, and their individuality was confirmed by Southern blotting.
For each construct, at least two separate cell lines were established from different culture dishes to ensure clonality of the cells and rule out as much as possible integration effects in the forthcoming experiments.
Transformation assay
Primary baby mouse kidney (BMK) cells were prepared from 3-to 6-day-old NMRI mice using standard procedures. Cells were plated at a density of 2 ϫ 10 5 cells/well in 6-well plates and subsequently cotransfected with 300 mg of the respective plasmids with DOSPER (Roche, Mannheim, Germany). After transfection, cells were transferred to 23-cm 2 flasks and grown for 3 weeks. Subsequently, cells were selected using medium containing 600 g/mL G418 for additional 2 weeks. Thereafter, the number of foci was determined.
Colony formation assay
BLM cells were seeded at a density of 1 ϫ 10 5 cells/well in 6-well plates and grown overnight. A total of 300 ng of plasmid was transfected with DOSPER according to the manufacturer's protocol. At 48 hours posttransfection, cells were plated in 10-cm dishes. After cells had attached, the medium was supplemented with 800 g/mL G418. The selection medium was changed every 3-4 days until foci appeared. Cells were washed and stained with Giemsa (Sigma, Deisenhofen, Germany), and colonies were counted.
Soft agar colony formation assay
A total of 5 ϫ 10 3 cells/well of the BLM cell line or the stable E1A transfectants were seeded in 6-well plates in DMEM, 12.5% FCS, containing 0.3% Bacto agar (Difco, Augsburg, Germany), overlying a basal layer of DMEM, 12.5% FCS, and 0.6% Bacto agar. The wells were cultured at 37°C for 3-4 weeks. Foci of Ͼ100 m in diameter were counted under a light microscope.
Tumorigenicity assays
For tumorigenicity assays, 3 ϫ 10 6 cells of the respective cell lines were injected subcutaneously into the right flank or the left shoulder of NMRI nu/nu mice. Tumor volumes were measured three times a week using calipers.
Western blot analysis
For the expression analysis of tumors, animals were sacrificed after tumors had reached the maximum acceptable size. Tu-mors were excised, frozen in liquid nitrogen, and ground to powder for the extraction of proteins. About 400 g of tumor powder was homogenized in a glass-glass homogenizer with cell lysis buffer and sonified thereafter. Western blotting was performed with 100 g of the obtained protein extract. E1A and protein kinase A ␣-cat expression was determined using the M73 and the C20 antibodies (Abs), respectively (both obtained from Santa Cruz, Heidelberg, Germany).
PCR analysis of tumor DNA
Genomic DNA from powdered tumors was prepared with the QIAamp tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. E1A cDNA was amplified using the E1A-specific primers and electrophoresed in a 1% agarose gel.
RESULTS
Construction of Ad5 E1A mutants
To obtain defined nontransforming E1A cDNA constructs, three mutants derived from the 289R proteinencoding 13S cDNA of Ad5 were cloned into the pRc-RSV expression vector, where gene expression is driven by the Rous sarcoma virus promoter. The 13S cDNA was chosen due to the reduced transforming activity of the 289R compared with the 12S mRNAencoded 243R protein. 28, 38, 41 The three constructs are depicted in Figure 1 : E1A delCR2 comprises the entire 13S cDNA sequence but lacks the sequences coding for the CR2. Thus, it should be nontransforming due to the lack of binding to p105-RB, which is required for transformation by E1A.
42-45 E1A delCR2 should, however, still bind to p300 and thus be able to down-regulate HER2/ neu transcription and induce lysis of tumor cells by natural killer cells. 46 E1A CR3Ex2 consists of the aminoterminal first methionine fused to the CR3 plus the second exon of Ad5 E1A. This mutant contains a strong transcriptional trans-activation domain within the CR3 and the CtBP-binding domain that resides in the second exon of E1A. Finally, E1A Ex2 is reduced to the second exon, leaving only the CtBP-binding domain and other carboxyterminal functions intact.
Transforming potential of E1A mutants It was first verified that our mutant E1A constructs were nontransforming using the adenoviral E1B gene as a cotransfectant in BMK cells (Table 1) . Transformed foci in BMK cell cultures transfected with the mutant E1A constructs plus E1B did not exceed the background number of foci obtained with the empty vector. In contrast, expression of E1A WT plus E1B revealed a transforming activity that was comparable with that of the products expressed from the wild-type Ad5 genomic E1A plus the E1B plasmid (Table 1) .
Thus, E1A delCR2 , E1A CR3Ex2 , and E1A Ex2 had lost the potential of E1A WT to immortalize cells or to contribute to the full malignant transformation in cooperation with E1B.
Generation of E1A mutant-expressing BLM cell lines After transfection of BLM cells with the E1A constructs, cells were selected in G418-containing medium. Of note, the E1A WT -and the E1A delCR2 -transfected cells produced only half the amount of G418-resistant colonies compared with the E1A CR3Ex2 -or E1A Ex2 -transfected cells, which produced as many colonies as the pRc-RSV control (Fig 2) . These differences might reflect a reduced cell growth in culture mediated by E1A WT or E1A delCR2 possibly due to the interaction of the ubiquitous transcriptional cofactors p300 and CBP with the aminoterminus and the CR1 of these E1A proteins.
Expression of the E1A genes in several colonies was confirmed for each transfectant by immunoblotting using a monoclonal anti-Ad5 E1A Ab (M73, see Materials and Methods). Some examples are shown in Figure 3 . Only a part of the G418-resistant clones expressed considerable amounts of the E1A proteins as judged by Western blot experiments. For our further experiments, we chose cell lines with comparable expression levels of E1A. Of note, the level of E1A expression was severalfold lower in these cell lines compared with the unhindered E1A expression in 293 cells. Cells were transfected with the respective E1A construct or the empty vector and a genomic Ad12 E1B fragment cloned into the pRc-RSV vector as described in Materials and Methods. The table shows the results of two independent experiments, each of which were performed in triplicate.
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Growth properties of BLM melanoma cells expressing E1A mutants in culture Analyzing the growth characteristics of BLM lines expressing the different E1A derivatives under normal cell culture conditions, we detected no substantial alterations in comparison with the parental cells. This corresponds with previous findings for several other cell lines. 5 Moreover, substantial changes in cell morphology were not observed (data not shown).
However, when the cells were assayed for their ability to grow anchorage independently in soft agar-containing medium, those lines containing the E1A WT construct or the E1A Ex2 mutant formed as many colonies as the parental BLM cells. In contrast, the colony-forming potential was markedly reduced in cells expressing the E1A delCR2 or the E1A CR3Ex2 mutant (Fig 4) . Thus, the E1A delCR2 and E1A CR3Ex2 exhibit tumor suppressor activities with respect to anchorage-independent growth of BLM cells, indicating an important role for the CR3 in this context. All E1A proteins were stably expressed for at least 14 passages of cell culture as detected by Western blot experiments (data not shown).
Tumorigenicity of BLM cell lines expressing E1A mutants in nude mice
An established model of tumorigenicity is the growth of human tumors as a xenograft on immunocompromised nude mice. Therefore, we subjected our E1A-expressing BLM cell lines to this test.
Three million low passage (Ͻ7) BLM cells were injected subcutaneously into the right shoulder (Fig 5A) or flank (Fig 5B) of the animals. In our first experiments, we compared tumor formation upon injection of parental BLM cells with that obtained with the E1A WT -, E1A delCR2 -, and E1A CR3Ex2 -expressing cell lines ( Fig  5A) . We found a distinct delay of 5-10 days in tumor formation in the case of cell lines expressing the E1A mutants compared with the parental BLM cell line. Unlike these findings, a delay of only 2-4 days was observed for the E1A WT -expressing cells (Fig 5A) .
The E1A Ex2 -expressing BLM cell lines revealed an onset and a characteristic of tumor growth like the parental BLM cell line (Fig 5B, upper panel) . This differed from the distinct delay in tumor growth observed with E1A CR3Ex2 -expressing lines and indicates that expression of exon 2 alone was not sufficient for suppression of BLM tumor growth in nude mice. The distinct inhibition of tumorigenicity we found when, in addition to exon 2, CR3 is present (E1A delCR2 or E1A CR3Ex2 ), shows that CR3 functions are required for an antitumorigenic function in our system. Interestingly, the presence of the aminoterminus, CR1, and CR2, and thus binding of, for example, p300, TATA-binding protein, and pocket proteins (p105-RB, p107, p130) seems to be not required in this context, because the E1A CR3Ex2 -and the E1A delCR2 -expressing cell lines revealed a comparable delay in the onset of BLM tumor growth (Fig 5B) . Most important, the mutants exceed the antitumorigenic capacity of E1A WT with respect to the generation of BLM-derived tumors.
Expression of E1A mutants in excised tumors
The delayed outgrowth of tumors from our cell lines in nude mice as observed in our experiments could be due either to the development of resistance to the antitumorigenic properties of E1A in a subset of inoculated cells or to the proliferation of a fraction of cells where the expression of the E1A transgene was down-regulated, rather than reflecting a defect on principle in the E1A-derived proteins to suppress the malignant phenotype.
Therefore, we tested the E1A expression in tumor extracts by immunoblotting. No expression of E1A proteins was found in tumors derived from cells expressing the E1A WT , E1A delCR2 , or E1A CR3Ex2 constructs, in contrast to those transfected with the E1A Ex2 mutants (Fig  6) . This loss of E1A expression seems to be due to a down-regulation at the transcriptional or the posttran- scriptional level, because PCR analysis showed that the DNA of E1A WT , E1A delCR2 , or E1A CR3Ex2 was present, and that the sequence of the former in the excised tumors was correct as revealed by sequence analysis (Fig  7) .
DISCUSSION
The finding of a strong and broad range of tumorsuppressive activity in many types of human cancer cells has made E1A a promising candidate for gene therapy of malignancies. However, one disadvantage of E1A is its ability to induce the immortalization and transformation of cells in cooperation with a viral or cellular oncogene, harboring the putative risk of a circumstantial support or even induction of tumorigenic growth. Although no tumor-inducing property of E1A in humans has been detected thus far, the existence of E1A/E1B-transformed human cells and principal considerations prompted us to generate transformation-defective E1A mutants and to test their antitumoral activity to improve the usefulness of E1A for human gene therapy.
As a result, we present Ad5 E1A derivatives that are fully transformation-defective but still retain tumorsuppressive activity in the BLM human metastatic melanoma cell line. This cell line was shown to be susceptible to tumor suppression by expression of genomic E1, and upon transfer of this gene it revealed a more normal cell morphology and sustained down-regulation of melanoma progression markers. 39 Therefore, this cell line was considered to be a well-suited test system for our main effort (i.e., the construction of safe transformationdeficient E1A-derived vectors).
The 289R protein expressed from the 13S mRNA of Ad5 has been shown to harbor an additional intrinsic transformation-repressing activity within the CR3 compared with the 243R protein translated from the 12S RNA product, and has successfully been used for tumor suppressor experiments by others. 41, 47 Therefore, the 13S cDNA was chosen as starting cDNA for our nontransforming E1A constructs.
Due to the antiproliferative and apoptosis-inducing activities of E1A, it is often problematic to obtain stable E1A-expressing cell lines without the presence of E1B. 39 This might explain the lower frequency of neo-resistant colonies when we tried to establish BLM cell lines expressing the E1A WT or the E1A delCR2 constructs in comparison with the pRc-RSV control. However, for the E1A CR3Ex2 and E1A Ex2 constructs, the frequency of neo-resistant colonies was as high as that for pRc-RSVtransfected cell lines.
Moreover, in any case of E1A expression in the neo-resistant colonies, the level of expression was weak when compared with Ad5 E1-transformed 293 cells. Thus, the E1A WT -and E1A delCR2 -expressing BLM cell lines, which were chosen randomly from those G418-resistant cells expressing detectable amounts of E1A proteins, cannot be ruled out to represent selectants that are adapted to the unhindered growth in cell culture. However, sequencing of the integrated cDNA, Western blotting, or transient transfection analysis gave no evidence for defective E1A proteins in these cells.
The E1A WT -, E1A delCR2 -, and E1A CR3Ex2 -expressing cell lines exhibited a reduced growth in soft agarcontaining medium and a considerable delay in the onset of tumor growth in nude mice. This is corroborated by the findings of others for different E1A 12SWT -transfected cell lines. 5 In our case, the greatest delay was detected for E1A CR3Ex2 -and E1A delCR2 -expressing cell lines, indicating that CR2 is not required for the suppression of BLM tumor growth. Notably, E1A WT , E1A delCR2 , and E1A CR3Ex2 proteins were no longer expressed in the outgrown tumors, suggesting that expression of these constructs does not allow BLM tumor growth in nude mice. In contrast, E1A Ex2 -expressing cells showed no delay in tumor growth compared with the BLM wildtype control; consequently, E1A Ex2 was expressed in the respective tumors. These data correspond with the results from the soft agar experiments and argue against an independent tumor-suppressive role of E1A exon 2 sequences in our system. Rather, CR3 seems to be required to express antitumorigenic properties in the case of the BLM and, as first experiments reveal, in the case of a H1299 lung carcinoma model (data not shown). These findings differ from results by others in which epidermoid cells were used; these investigators reported the requirement of CR2 sequences for antitumorigenic effects by E1A in an experimental system. 47 Moreover, we found no tumor-suppressive activity of exon 2 alone in our systems as described by Paul et al. 48 In conclusion, our data show that CR3 plus exon 2 of Ad5 E1A are sufficient to suppress the tumor growth of E1A-expressing cells in nude mice and that neither aminoterminal sequences nor CR1/CR2 are required for antioncogenic functions of E1A in BLM cells. These findings are in part different from the results obtained with other cell lines, 7, [47] [48] [49] indicating that distinct and possibly cell type-and tumor-specific properties of the multifunctional E1A protein seem to be required for the suppression of different kinds of tumors. Future work will further elucidate the requirements of the multiple E1A functions and the role of the corresponding E1A-interacting cellular factors for the suppression of a given neoplastic disease.
